<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

DBV Technologies initiated with a Buy at Guggenheim

PremiumThe Fly

10d ago

Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments

PremiumRatings

23d ago

DBV Technologies announces last patient visit completed in VITESSE trial

PremiumThe Fly

1M ago

DBV Technologies appoints Kevin Trapp as chief commercial officer

PremiumThe Fly

1M ago

PremiumThe FlyDBV Technologies price target raised to $20 from $16 at H.C. Wainwright

2M ago

The Fly

DBV Technologies reports Q3 GAAP EPS (24c), consensus (29c)

2M ago

Company Announcements

Dbv Technologies Advances Peanut Allergy Treatment for Toddlers: A Study Update

2M ago

0QAJ Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

2M ago

PremiumRatings

Optimistic Outlook for DBV Technologies Amid Promising Viaskin Peanut Advancements

2M ago

DBV Technologies to sell $30M of ADSs through at-the-market program

PremiumThe Fly

2M ago

Dbv Technologies Advances Peanut Allergy Treatment with New Phase 3 Study

PremiumCompany Announcements

4M ago

PremiumCompany AnnouncementsDbv Technologies’ Peanut Allergy Patch Study: A Promising Update for Investors

4M ago

Dbv Technologies Advances Peanut Allergy Treatment with New Study Update

Company Announcements

Dbv Technologies Advances Peanut Allergy Treatment with New Study Update

4M ago

DBV Technologies’ Viaskin Peanut Program: Strategic Advancements and Regulatory Pathways Pave the Way for Investment Opportunities

Ratings

DBV Technologies’ Viaskin Peanut Program: Strategic Advancements and Regulatory Pathways Pave the Way for Investment Opportunities

5M ago

DBV Technologies: Advancing Viaskin Peanut Towards FDA Approval with Strong Financial Backing

PremiumRatings

5M ago

DBV Technologies appoints James Briggs as chief human resources officer

PremiumThe Fly

5M ago

Dbv Technologies Advances Peanut Allergy Patch Study for Toddlers

PremiumCompany Announcements

5M ago

Dbv Technologies’ Peanut Allergy Study: A Potential Game-Changer for Pediatric Treatment

PremiumCompany Announcements

5M ago

PremiumRatingsPositive Outlook for DBV Technologies SA Driven by Promising Phase 3 Trial and Market Expansion Potential for Viaskin Peanut

6M ago

Company Announcements

DBV Technologies’ Peanut Allergy Patch Study: A Promising Step Forward

6M ago

DBV Technologies announces first subject screened in COMFORT Toddlers trial

The Fly

DBV Technologies announces first subject screened in COMFORT Toddlers trial

6M ago